Disc Medicine

Last updated: January 17, 2024

John Quisel, CEO
John Quisel, CEO
Country: USA | Funding: $414.8M (+)

Website: https://www.discmedicine.com

Disc Medicine is a hematology company that hopes can become the first disease-modifying treatment for erythropoietic porphyrias, a family of rare and debilitating genetic disorders caused by dysregulated heme synthesis.